In a recent interview following the 2026 ASCO Genitourinary Cancers Symposium, Karie Danielle Keera Runcie, MD, assistant ...

For oncologists navigating the rapidly evolving landscape of renal cell carcinoma (RCC), the data presented at the 2026 ASCO ...

This insight piece explores how treatment patterns in bladder cancer have shifted as immunotherapy options have expanded in community oncology. You’ll learn how combination regimens such as enfortumab ...

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has fully approved a Japanese patent covering the Company’s proprietary use of Ampligen ...

Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY(R) ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for ...

Dr. Aleksander Słusarczyk presented the clinical case of a 75-year-old woman who presented with a two-month history of hematuria. Her medical history was notable for diabetes, prior myocardial ...

Dr. Alexandre Zlotta delivered the State-of-the-art lecture Who really needs surgery after neo-adjuvant chemotherapy? Dr.

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility AnalysisSYDNEY, AUSTRALIA, March 13, 2026 ...

Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS ...

Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.